Angiopoietin-2 is a negative prognostic marker in small cell lung cancer

被引：24

作者：

Canadas, Israel ^{[1
]}

Taus, Alvaro ^{[2
]}

Villanueva, Xavier ^{[2
]}

Arpi, Oriol ^{[1
]}

Pijuan, Lara ^{[3
]}

Rodriguez, Yara ^{[1
]}

Menendez, Silvia ^{[1
]}

Mojal, Sergi ^{[4
]}

Rojo, Federico ^{[5
]}

Albanell, Joan ^{[1
,2
,6
]}

Rovira, Ana ^{[1
,2
]}

Arriola, Edurne ^{[1
,2
]}

机构：

[1] Hosp del Mar, Res Inst, IMIM, Canc Res Program, Barcelona 08003, Spain

[2] Hosp del Mar, Dept Oncol, Barcelona 08003, Spain

[3] Hosp del Mar, Dept Pathol, Barcelona 08003, Spain

[4] IMIM, Consulting Serv Methodol Biomed Res, Barcelona, Spain

[5] IIS Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain

[6] Univ Pompeu Fabra, Barcelona, Spain

来源：

LUNG CANCER | 2015年 / 90卷 / 02期

关键词：

Small cell lung cancer (SCLC); Chemoresistance; Angiogenesis; Angiopoietin-2; PHASE-II; MESENCHYMAL TRANSITION; CHEMOTHERAPY; MET; BEVACIZUMAB; COMBINATION; METASTASIS; INHIBITOR; CARCINOMA; INTEGRIN;

D O I：

10.1016/j.lungcan.2015.09.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Small cell lung cancer (SCLC) is a highly lethal disease due to its chemorefractoly nature after initial treatment. Angiogenesis plays an important role in tumor growth, metastasis and chemoresistance. We hypothesized that angiogenesis could predict chemoresistance in SCLC patients and be potentially a therapeutic target in this disease. Methods: Serum samples from forty-three SCLC patients were prospectively obtained at diagnosis, response evaluation and progression. Angiogenesis-related cytokines (Angiopoietin-2, VEGF-A, C and D) were simultaneously quantified by Luminex Technology. Clinical data were prospectively recorder. Results: Significantly higher concentration of angiogenesis-related cytokines were found in SCLC patients at diagnosis compared to healthy volunteers. High baseline serum concentration of Angiopoietin-2 (sAngiopoietin-2) were associated with a worse overall survival (p = 0.006) and remained independently associated with survival in the multivariate analysis (p = 0.008). In addition, sAngiopoietin-2 significantly increased at progression when compared to baseline. Conclusion: These data provide novel evidence on a role of sAngiopoietin-2 in the adverse clinical behavior of SCLC and could be a potential therapeutic target in this disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：302 / 306

页数：5

共 27 条

[1]

Alexander P., 2015, J CLIN ONCOL S, V33

[2] Prognostic Impacts of Angiopoietins in NSCLC Tumor Cells and Stroma: VEGF-A Impact Is Strongly Associated with Ang-2 [J].

Andersen, Sigve ;

Donnem, Tom ;

Al-Shibli, Khalid ;

Al-Saad, Samer ;

Stenvold, Helge ;

Busund, Lill-Tove ;

Bremnes, Roy M. .

PLOS ONE, 2011, 6 (05)

[3]

Arnold AM, 2007, J CLIN ONCOL, V25, P4278, DOI 10.1200/JCO.2007.12.3083

[4] MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines [J].

Arriola, E. ;

Canadas, I. ;

Arumi-Uria, M. ;

Domine, M. ;

Lopez-Vilarino, J. A. ;

Arpi, O. ;

Salido, M. ;

Menendez, S. ;

Grande, E. ;

Hirsch, F. R. ;

Serrano, S. ;

Bellosillo, B. ;

Rojo, F. ;

Rovira, A. ;

Albanell, J. .

BRITISH JOURNAL OF CANCER, 2011, 105 (06) :814-823

[5] Genetic changes in small cell lung carcinoma [J].

Arriola, Edurne ;

Canadas, Israel ;

Arumi, Montse ;

Rojo, Federico ;

Rovira, Ana ;

Albanell, Joan .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (04) :189-197

[6] High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients [J].

Canadas, Israel ;

Taus, Alvaro ;

Gonzalez, Iria ;

Villanueva, Xavier ;

Gimeno, Javier ;

Pijuan, Lara ;

Domine, Manuel ;

Sanchez-Font, Albert ;

Vollmer, Ivan ;

Menendez, Silvia ;

Arpi, Oriol ;

Mojal, Sergi ;

Rojo, Federico ;

Rovira, Ana ;

Albanell, Joan ;

Arriola, Edurne .

ONCOTARGET, 2014, 5 (14) :5246-5256

[7] Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer [J].

Canadas, Israel ;

Rojo, Federico ;

Taus, Alvaro ;

Arpi, Oriol ;

Arumi-Uria, Montserrat ;

Pijuan, Lara ;

Menendez, Silvia ;

Zazo, Sandra ;

Domine, Manuel ;

Salido, Marta ;

Mojal, Sergi ;

Garcia de Herreros, Antonio ;

Rovira, Ana ;

Albanell, Joan ;

Arriola, Edurne .

CLINICAL CANCER RESEARCH, 2014, 20 (04) :938-950

[8] Targeting the tumour vasculature: insights from physiological angiogenesis [J].

Chung, Alicia S. ;

Lee, John ;

Ferrara, Napoleone .

NATURE REVIEWS CANCER, 2010, 10 (07) :505-514

[9] Circulating Ang-2 Mrna Expression Levels: Looking ahead to a New Prognostic Factor for NSCLC [J].

Coelho, Ana L. ;

Araujo, Antonio ;

Gomes, Monica ;

Catarino, Raquel ;

Marques, Agostinho ;

Medeiros, Rui .

PLOS ONE, 2014, 9 (02)

[10] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].

Faivre, S ;

Delbaldo, C ;

Vera, K ;

Robert, C ;

Lozahic, S ;

Lassau, N ;

Bello, C ;

Deprimo, S ;

Brega, A ;

Massimini, G ;

Armand, JP ;

Scigalla, P ;

Raymond, E .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35

← 1 2 3 →